Karyopharm Therapeutics Inc. (KPTI) EPS Estimated At $-0.58

February 15, 2018 - By Vivian Park

 Karyopharm Therapeutics Inc. (KPTI) EPS Estimated At $ 0.58
Investors sentiment increased to 2.5 in 2017 Q3. Its up 0.94, from 1.56 in 2017Q2. It increased, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported.
Bancshares Of New York Mellon holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 163,810 shares. Sg Americas Securities Ltd Liability Corporation holds 13,116 shares or 0% of its portfolio. Alliancebernstein L P holds 0% or 43,430 shares in its portfolio. New York State Common Retirement Fund has invested 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Art Advisors Lc invested in 26,552 shares. Palo Alto Invsts Ltd Liability Co holds 3.50M shares. 307,200 are held by Jpmorgan Chase And. Voya Investment Management Ltd Liability Corp has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 15,008 shares. Prelude Mngmt Ltd Limited Liability Company holds 0% or 1,800 shares in its portfolio. D E Shaw Com, New York-based fund reported 60,549 shares. Vanguard Inc reported 1.77M shares. Wellington Mgmt Llp owns 6.29M shares. Proshare Advisors Limited Co stated it has 28,871 shares. The New York-based Blackrock has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Tekla Cap Mngmt Limited Liability Com holds 0.3% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 756,679 shares.

Since August 29, 2017, it had 0 buys, and 17 selling transactions for $1.27 million activity. $22,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Primiano Christopher Brett. 1,500 shares were sold by Mirza Mansoor Raza, worth $19,500 on Wednesday, February 7. $91,553 worth of stock was sold by Kauffman Michael on Monday, December 18.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.58 EPS on March, 15.They anticipate $0.07 EPS change or 10.77 % from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -10.77 % EPS growth. The stock increased 3.04% or $0.44 during the last trading session, reaching $14.92. About 378,370 shares traded or 84.91% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 15, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, March 15, the company rating was maintained by Jefferies. Leerink Swann maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Tuesday, August 11 with “Outperform” rating. The firm has “Buy” rating by RBC Capital Markets given on Monday, October 16. Jefferies initiated Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Wednesday, September 9. Jefferies has “Buy” rating and $23 target. The firm earned “Buy” rating on Friday, June 23 by Cantor Fitzgerald. H.C. Wainwright reinitiated it with “Buy” rating and $23 target in Wednesday, November 15 report. The firm has “Overweight” rating by JP Morgan given on Wednesday, September 2. The firm has “Overweight” rating by JP Morgan given on Monday, March 14. The firm has “Underperform” rating by Bank of America given on Tuesday, March 15. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Monday, September 11.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $739.04 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More important recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Globenewswire.com which released: “Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment …” on January 25, 2018, also Seekingalpha.com published article titled: “What’s Next For Karyopharm Therapeutics?”, Globenewswire.com published: “Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule …” on February 01, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was released by: Seekingalpha.com and their article: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” with publication date: June 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.